# LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma

> **NCT04479241** · PHASE2 · COMPLETED · sponsor: **Istari Oncology, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Glioblastoma
- Recurrent Glioblastoma
- Supratentorial Glioblastoma
- Brain Tumor

## Interventions

- **BIOLOGICAL:** lerapolturev
- **BIOLOGICAL:** pembrolizumab

## Key facts

- **NCT ID:** NCT04479241
- **Lead sponsor:** Istari Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-21
- **Primary completion:** 2024-06-05
- **Final completion:** 2024-06-21
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04479241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04479241, "LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04479241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*